May 2, 2022 - Johnson and Johnson

03/21/2022 – Policy Notice

Can CE get 340B pricing if they share claims data?

Yes

Are system owned contract pharmacies exempted from this policy?

Yes

Can CEs with no in-house pharmacy designate a contract pharmacy for 340B pricing access?

Yes

Drugs affected by this policy:

“STELARA®
TREMFYA®
SIMPONI ARIA®
SIMPONI®
REMICADE®
XARELTO®
INVOKAMET®
INVOKAMET® XR
INVOKANA®
DARZALEX®
DARZALEX FASPRO®
ERLEADA®
INVEGA HAFYERA™
INVEGA SUSTENNA ®
INVEGA TRINZA®
INVEGA®
OPSUMIT®
UPTRAVI®
TRACLEER®
VELETRI®
SYMTUZA®
PREZCOBIX®
PREZISTA®
ZYTIGA®
PROCRIT®
EDURANT®
ELMIRON®
TOPAMAX®
YONDELIS®”

Policy applies to what entity types?

Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.

Important FAQs/Information

Covered Entities that do not submit the requested claims data are permitted to designate (i) one PAH in-network specialty contract pharmacy location for PAH covered outpatient drugs and (ii) for all other Janssen covered outpatient drugs, another contract pharmacy location, if they decline to provide the requested limited claims data, lack an in-house pharmacy, and that contract pharmacy and location are registered on the HRSA database.